Company performance
Add to research
Current Price
as of Mar 17, 2025$3.54
P/E Ratio
N/A
Market Cap
$231.58M
- GRE
Description
Add to research
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.
Metrics
Add to research
Overview
- HQBarcelona, CT
- SectorHealth Technology
- IndustryBiotechnology
- TickerORY
- Price$3.536626+13.55%
Trading Information
- Market cap$231.58M
- Float82.95%
- Average Daily Volume (1m)2,367,550
- Average Daily Volume (3m)875,882
- EPS-$0.06
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$3.67M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$4.33M
- EV$98.58M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B2.33
- Debt/Equity20.30
Documents
Add to research
Factset Street Account